News

Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to isatuximab.

Scientists have developed a fast lab-based approach, creating positive co-dependent relationships between hosts and bacteria - termed ‘mutualisms’. These lab-developed bacterial relationships demonstrate how microbes can work with their hosts to prevent infection.

Researchers have shown that one olfactory receptor plays a critical role in the progression of prostate cancer. They found that activating an olfactory receptor called OR51E2 in prostate cancer cells caused the cancer to morph into the more aggressive form of the disease.

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.

Chemist Matthew D. Disney, PhD has developed a small-molecule-based tool that acts on RNA to selectively delete certain gene products. This deletion tool opens the possibility of creating drugs that can be taken conveniently as pills to correct genetic diseases.

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, researchers have shown that a new class of drugs is also effective against aggressive, hard-to-treat tumors such as lung and pancreatic cancers.

A new study, affiliated with UNIST has recently presented a novel statistical algorithm, capable of identifying potential disease genes in a more accurate and cost-effective way. This algorithm has also been considered as a new promising approach for the identification of candidate disease genes, as it works effectively with less genomic data and takes only a minute or two to get results.

The increase of skyscrapers in a city resembles the development of some living systems. Spanish researchers have created an evolutionary genetic algorithm that, on the basis of the historical and economic data of an urban area, can predict what its skyline could look like in the coming years. The method has been applied successfully to the thriving Minato Ward, in Tokyo.

Under the agreement, Shuwen will develop companion diagnostics for Bliss’ oncology drug candidates. Shuwen also commits to provide testing services in its CAP-certified central labs for BlissBio’ clinical trials. The terms of the collaboration are undisclosed.

Researchers have shown for the first time that a form of artificial intelligence or machine learning known as a deep learning convolutional neural network (CNN) is better than experienced dermatologists at detecting skin cancer.